Learning disabilities

New Report Identifies Unique Challenges for LGBT Community Facing Alzheimer's and Other Dementias

Retrieved on: 
Tuesday, August 14, 2018
Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Neuroscience, Health, Dementia, Alzheimer's disease, Hypercholesterolemia, Services & Advocacy for GLBT Elders, Gerodiversity

Several studies document that LGBT elders access essential services, including visiting nurses, food stamps, senior centers, and meal plans, much less frequently than the general aging population.

Key Points: 
  • Several studies document that LGBT elders access essential services, including visiting nurses, food stamps, senior centers, and meal plans, much less frequently than the general aging population.
  • Risk factors for heart disease including diabetes, tobacco use, high blood pressure and high cholesterol are also risk factors for Alzheimer's and stroke-related dementia.
  • Among the 16 recommendations for organizations and service providers, the Alzheimer's Association and SAGE suggest:
    Expand your definition of family.
  • SAGE is the country's largest and oldest organization dedicated to improving the lives of lesbian, gay, bisexual, and transgender (LGBT) older people.

BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai

Retrieved on: 
Tuesday, August 7, 2018
Medicine, Clinical medicine, Biology, Psychiatric diagnosis, RTT, Cognitive disorders, Learning disabilities, Neurological disorders, Alzheimer's disease, Neurodegeneration, Parkinson's disease, Biomarker

The disease development in Alzheimer's disease likely starts several years before the patient shows any clinical symptoms.

Key Points: 
  • The disease development in Alzheimer's disease likely starts several years before the patient shows any clinical symptoms.
  • The disease also has a progressive development, which means that the symptoms increase as the disease progresses.
  • Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease.
  • BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai

Retrieved on: 
Tuesday, August 7, 2018
Medicine, Clinical medicine, Biology, Psychiatric diagnosis, RTT, Cognitive disorders, Learning disabilities, Neurological disorders, Alzheimer's disease, Neurodegeneration, Parkinson's disease, Biomarker

The disease development in Alzheimer's disease likely starts several years before the patient shows any clinical symptoms.

Key Points: 
  • The disease development in Alzheimer's disease likely starts several years before the patient shows any clinical symptoms.
  • The disease also has a progressive development, which means that the symptoms increase as the disease progresses.
  • Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease.
  • BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Global Alzheimer's Disease Therapeutics and Diagnostics Market 2018-2028

Retrieved on: 
Monday, August 6, 2018
Medicine, Biology, Clinical medicine, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Biotechnology, Alzheimer's disease, Biomarker

LONDON, August 6, 2018 /PRNewswire/ -- Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies

Key Points: 
  • LONDON, August 6, 2018 /PRNewswire/ -- Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies
    The Alzheimer's Disease Therapeutics and Diagnostics Market will reach $7.93bn in 2018.
  • The Alzheimer's Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 12.1% in the second half of the forecast period.
  • The 208-page report provides clear detailed insight into the Alzheimer's Disease Therapeutics and Diagnostics Market.
  • - Alzheimer's Disease Market forecasts from 2018-2028, further broken down into:
    - Quantitative analysis of the Alzheimer's drug market from 2018 to 2028.

New Research Shows Natural Antioxidant Pycnogenol® Effective in Improving Symptoms of Mild Cognitive Impairment

Retrieved on: 
Thursday, August 2, 2018
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Cognition, Health, RTT, Dementia, Mild cognitive impairment, Cognitive deficit

HOBOKEN, N.J., Aug. 2, 2018 /PRNewswire/ --A new peer-reviewed study shows that daily supplementation with the natural super-antioxidant Pycnogenol (pic-noj-en-all) can be instrumental in improving the symptoms of Mild Cognitive Impairment (MCI) a potential risk factor for early onset dementia and other degenerative cognitive conditions.

Key Points: 
  • HOBOKEN, N.J., Aug. 2, 2018 /PRNewswire/ --A new peer-reviewed study shows that daily supplementation with the natural super-antioxidant Pycnogenol (pic-noj-en-all) can be instrumental in improving the symptoms of Mild Cognitive Impairment (MCI) a potential risk factor for early onset dementia and other degenerative cognitive conditions.
  • This study shows promising results for Pycnogenol to support healthy brain function and overall cognitive health," said Dr. Lamm.
  • This new study builds upon previous research supporting the benefits of Pycnogenol for cognitive health improvement.
  • Pycnogenol is a powerful super-antioxidant shown in decades of research to boost blood circulation and act as a natural anti-inflammatory.

Neurim Pharmaceuticals Receives Positive CHMP Opinion for Slenyto (Pediatric Prolonged-Release Melatonin) for the Treatment of Insomnia in Children With Autism Spectrum Disorder (ASD)

Retrieved on: 
Monday, July 30, 2018
Autism, Psychiatry, Abnormal psychology, Psychiatric diagnosis, Learning disabilities, Neuroscience, Autism spectrum, Developmental neuroscience, Developmental psychology

"The positive CHMP opinion of our PedPRM formulation represents a significant milestone in addressing an unmet need for ASD children who suffer severely from impaired sleep.

Key Points: 
  • "The positive CHMP opinion of our PedPRM formulation represents a significant milestone in addressing an unmet need for ASD children who suffer severely from impaired sleep.
  • Adjusting the dosage according to individual response was easy and the formulation was exceptionally well tolerated in this population.
  • Related measures of children's daytime mood and behaviours also improve with this treatment, as does the parental quality of life.
  • The treatment will address a significant need in the medical management of some children and adolescents with autistic spectrum disorders."

Brain Disease Research Organizations Pledge $2 Million USD to Uncover Similarities and Differences across Spectrum of Disorders

Retrieved on: 
Thursday, July 26, 2018
Psychiatric diagnosis, RTT, Psychiatry, Health, Cognitive disorders, Medicine, Aging-associated diseases, Learning disabilities, Alzheimer's Research UK, Neurodegeneration, Dementia, Parkinson's disease

NEW YORK,CHICAGO, TORONTO andLONDON, July 26, 2018 /PRNewswire/ --Four leading supporters of brain disease research are continuing a global funding initiative to uncover similarities and differences across neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases.

Key Points: 
  • NEW YORK,CHICAGO, TORONTO andLONDON, July 26, 2018 /PRNewswire/ --Four leading supporters of brain disease research are continuing a global funding initiative to uncover similarities and differences across neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases.
  • Fox Foundation for Parkinson's Research and the Alzheimer's Association in the United States, the Weston Brain Institute in Canada, and Alzheimer's Research UK in the United Kingdom.
  • "Better defining similarities and differences across conditions can help us measure and treat brain disorders based more on an individual's biology rather than on an umbrella diagnosis.
  • We are currently supporting pioneering dementia research projects worth over 31 million in leading Universities across the UK.

Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

Retrieved on: 
Wednesday, July 25, 2018
Health, Cognitive disorders, Medicine, Psychiatry, Learning disabilities, Psychiatric diagnosis, RTT, Abnormal psychology, Alzheimer's disease, Clinical trial, Clinical Dementia Rating, Dementia

The clinical endpoints of Alzheimer's Disease Composite Score (ADCOMS), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Clinical Dementia Rating Sum of Boxes (CDR-SB) were also assessed from baseline to 18 months of treatment.

Key Points: 
  • The clinical endpoints of Alzheimer's Disease Composite Score (ADCOMS), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Clinical Dementia Rating Sum of Boxes (CDR-SB) were also assessed from baseline to 18 months of treatment.
  • BAN2401 demonstrated a dose-dependent reduction in amyloid plaques as measured by amyloid PET, and this reduction was statistically significant at all doses.
  • At 18 months, slowing of clinical decline for the highest treatment dose of BAN2401 compared to placebo on CDR-SB was 26%.
  • Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

Alzheimer Disease Report 2018 - New Drugs, Markets and Companies - Profiles of 119 Companies

Retrieved on: 
Wednesday, July 25, 2018
Psychiatry, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Neuroscience, Abnormal psychology, Alzheimer's disease, Biology

The "Alzheimer Disease - New Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer Disease - New Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • Alzheimer's disease market in the seven major markets is analyzed for the year 2017.
  • As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.
  • Profiles of 119 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 82 collaborations.

AAIC® 2018 Features First Clinical Trial to Show Intensive Blood Pressure Treatment Reduces New Cases of Mild Cognitive Impairment and Dementia (Combined Endpoint)

Retrieved on: 
Wednesday, July 25, 2018
Hypertension, Cognitive disorders, Aging-associated diseases, Learning disabilities, Psychiatric diagnosis, Medicine, Psychiatry, Health, Dementia, Systolic Blood Pressure Intervention Trial, Management of hypertension, Blood pressure

At AAIC 2018, researchers reported preliminary results related to risk of dementia and cognitive decline from the Systolic Blood Pressure Intervention Trial ( SPRINT ).

Key Points: 
  • At AAIC 2018, researchers reported preliminary results related to risk of dementia and cognitive decline from the Systolic Blood Pressure Intervention Trial ( SPRINT ).
  • SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) examined whether treating for the lower blood pressure target reduces the risk of developing dementia and/or MCI.
  • In SPRINT MIND, the researchers found a statistically significant 19 percent lower rate of new cases of MCI in the intensive blood pressure treatment group.
  • The combined outcome of MCI plus probable all-cause dementia was 15 percent lower in the intensive versus standard treatment group.